Year 2022 / Volume 29 / Number 1

Abstract PDF HTML

Original

Use of 8 % capsaicin patches for the treatment of lumbar neuropathic pain

Rev. Soc. Esp. Dolor. 2022; 29(1): 28-33 / DOI: 10.20986/resed.2022.3995/2022

María del Mar López, José López, José López, Martín García


ABSTRACT

Introduction: Lumbar neuropathic pain is a common pathology in daily clinical practice, with a complex treatment, both pharmacological and interventional. These treatments can be complemented with an 8 % capsaicin transdermal patch. Capsaicin is a selective agonist of TRPV1 receptors (transient receptor vanilla 1) whose activation blocks the release of substance P, which is heavily involved in the inflammatory process.
Objectives: To assess the usefulness of the capsaicin 8 % patch as an adjunct in patients with lumbar neuropathic pain. As a secondary objective, to assess the adverse effects of the capsaicin patch both at the time of application and after 3 months.
Patients and methods: Retrospective, observational and descriptive study, which included 20 patients with lumbar neuropathic pain, treated with capsaicin patch 8 % (Qutenza®) as an adjunct to the usual treatment of this pathology. Three tests were used to assess pain: VAS (visual analogue pain scale), DN4 and LANSS for neuropathic pain. The 3 tests were administered to the patients before the application of the patch and 3 months after the patch was applied.
Outcomes: At baseline, 95 % of patients included in the study had very severe pain (VAS 8-9). At 3 months, 85 % of patients reported moderate pain (VAS 5-6). With respect to the DN4 test, we observed a decrease in values of slightly more than 2 points. In the LANSS test we found a decrease of more than 5 points in these 3 months. The application of the patch did not cause significant side effects.
Conclusions: The 8 % capsaicin patch has been shown to be effective and safe as an adjunctive treatment for lumbar neuropathic pain.



RESUMEN

Introducción: El dolor neuropático lumbar es una patología frecuente en la clínica diaria, con un tratamiento complejo, tanto farmacológico como intervencionista. Estos tratamientos podemos complementarlos con un parche transdérmico de capsaicina al 8 %. La capsaicina es agonista selectivo de los receptores TRPV1 (receptor transitorio vanilla de 1) cuya activación bloquea la liberación de sustancia P, muy implicada en el proceso de la inflamación.
Objetivos: Valorar la utilidad del parche de capsaicina al 8 % como complemento en pacientes con dolor neuropático lumbar. Como objetivo secundario, valorar los efectos adversos del parche de capsaicina tanto en el momento de aplicación como a los 3 meses.
Pacientes y métodos: Estudio retrospectivo, observacional y descriptivo, en el que se incluyeron 20 pacientes con dolor neuropático lumbar, tratados con parche de capsaicina al 8 % (Qutenza®) como complemento al tratamiento habitual de esta patología. Se utilizaron 3 test para valorar el dolor: EVA (escala visual analógica del dolor), DN4 y LANSS para dolor neuropático. Los 3 test fueron pasados a los pacientes antes de la aplicación del parche y a los 3 meses de este.
Resultados: Al inicio, el 95 % de los pacientes incluidos en el estudio presentaban dolor muy severo (EVA 8-9). A los 3 meses, el 85 % de los pacientes refieren dolor moderado (EVA 5-6). Con respecto al test DN4 observamos una disminución de los valores de algo más de 2 puntos. En el test LANSS encontramos una disminución de más de 5 puntos en estos 3 meses. La aplicación del parche no causó efectos secundarios significativos.
Conclusiones: El parche de capsaicina al 8 % se ha mostrado eficaz y seguro como tratamiento complementario para el dolor neuropático lumbar.





Complete Article

Nuevo comentario

Security code:
CAPTCHA code image
Speak the codeChange the code
 

Comentarios

No comments in this article

Bibliografía

1. Bendaña JE. Dolor neuropático: actualización en definiciones y su tratamiento farmacológico. Rev Med Hondureña. 2020;88(1):48-51.
DOI: 10.5377/rmh.v88i1.11591
2. Neuropathic pain in adults: pharmacological management in non-specialist settings Clinical guideline [Internet]. Nationa Institute for Health and Care Excellence; 2013. Disponible en: www.nice.org.uk/guidance/cg173
3. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-73.
DOI: 10.1016/S1474-4422(14)70251-0
4. Carvajal AMR, Osorio CAO, Rojas SM, Bernal I. Recomendaciones basadas en la evidencia para el manejo del dolor neuropático (revisión de la literatura). Rev Soc Esp Dolor. 2018;25(6):349-58. DOI: 10.20986/resed.2018.3673/2018
DOI: 10.20986/resed.2018.3673/2018
5. Baron R, Binder A, Attal N, Casale R, Dickenson AH, Treede RD. Neuropathic low back pain in clinical practice. Eur J Pain. 2016;20(6):861-73.
DOI: 10.1002/ejp.838
6. Kocot-Kępska M, Zajączkowska R, Mika J, Kopsky DJ, Wordliczek J, Dobrogowski J, et al. Topical Treatments and Their Molecular/Cellular Mechanisms in Patients with Peripheral Neuropathic Pain-Narrative Review. Pharmaceutics. 2021;13(4):450.
DOI: 10.3390/pharmaceutics13040450
7. van Nooten F, Treur M, Pantiri K, Stoker M, Charokopou M. Capsaicin 8 % Patch Versus Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: A Systematic Literature Review and Network Meta-analysis. Clinical Therapeutics. 2017;39(4):787-803.e18.
DOI: 10.1016/j.clinthera.2017.02.010
8. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107(4):490-502.
DOI: 10.1093/bja/aer260
9. Zis P, Bernali N, Argira E, Siafaka I, Vadalouka A. Effectiveness and Impact of Capsaicin 8% Patch on Quality of Life in Patients with Lumbosacral Pain: An Open-label Study. Pain Physician. 2016;19(7):E1049-53.
DOI: 10.36076/ppj/2016.19.E1049
10. Derry S, Rice AS, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;1(1):CD007393.
DOI: 10.1002/14651858.CD007393.pub4
11. Blair HA. Capsaicin 8 % Dermal Patch: A Review in Peripheral Neuropathic Pain. Drugs. 2018;78(14):1489-500.
DOI: 10.1007/s40265-018-0982-7
12. Ficha técnica de capsaicina 8 % [Internet]. Agencia Española de Medicamentos y Productos Sanitarios; 2019.
13. Pérez C, Gálvez R, Insausti J, Bennett M, Ruiz M, Rejas J, et al. Adaptación lingüística y validación al castellano de la escala LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) para el diagnóstico diferencial del dolor neuropático. Medicina Clinica. 2006;127(13):485-91.
DOI: 10.1157/13093266
14. Blanco E, Galvez R, Zamorano E, López V, Pérez M. Prevalencia del dolor neuropático (DN), según DN4, en atención primaria. Semergen. 2012;38(4):203-10.
DOI: 10.1016/j.semerg.2011.10.012
15. Vicente Herrero MT, Delgado Bueno S, Bandrés Moyá F, Ramírez Iñiguez de la Torre MV, Capdevila García L. Valoración del dolor. Revisión comparativa de escalas y cuestionarios. Rev Soc Esp Dolor. 2018;25(4):228-36. DOI: 10.20986/resed.2018.3632/2017.
DOI: 10.20986/resed.2018.3632/2017
16. Bennett M. La Escala de Dolor de LANSS: la evaluación de síntomas neuropáticos de Leeds. Rev Soc Esp Dolor. 2002;9(2):74-87.

Artículos relacionados

Pain trajectories and neuropathic pain symptoms following lung cancer surgery: a prospective cohort study

Rev. Soc. Esp. Dolor. 2023; 30(4): 270-283 / DOI: 10.1002/ejp.2265

Abdominopelvic neuropathic pain secondary to involvement of the anterior cutaneous, iliohypogastric, and ilioinguinal nerves: case report and review of the literature

Rev. Soc. Esp. Dolor. 2023; 30(4): 265-269 / DOI: 10.20986/resed.2024.4054/2023

Exosomes as a potential therapeutic strategy for low back pain: literature review

Rev. Soc. Esp. Dolor. 2023; 30(4): 243-249 / DOI: 10.20986/resed.2023.4075/2023

Continuous electrical stimulation for the treatment of trigeminal neuralgia. A systematic review

Rev. Soc. Esp. Dolor. 2023; 30(4): 217-226 / DOI: 10.20986/resed.2023.4043/2022

Impact on quality of life, depression and analgesic use, are associated with suffering in fibromyalgia patients. A cross-sectional study

Rev. Soc. Esp. Dolor. 2023; 30(3): 159-167 / DOI: 10.20986/resed.2023.4061/2023

A road trip to chemotherapy-induced neuropathic pain

Rev. Soc. Esp. Dolor. 2023; 30(3): 155-156 / DOI: 10.20986/resed.2023.4110/2023

Pain paths among post-COVID-19 condition subjects: a prospective cross-sectional study with in-person evaluation

Rev. Soc. Esp. Dolor. 2023; 30(2): 131-145 / DOI: 10.1002/ejp.2094

Effect of therapeutic exercise in persons with sacroiliac joint dysfunction: a systematic review and meta-analysis

Rev. Soc. Esp. Dolor. 2023; 30(2): 95-108 / DOI: 10.20986/resed.2023.4034/2022

Not just low back pain: atypical manifestation of aortic aneurysm

Rev. Soc. Esp. Dolor. 2023; 30(1): 60-62 / DOI: 10.20986/resed.2022.3983/2022

Effectiveness of cluneal nerve block for the treatment of chronic low back pain

Rev. Soc. Esp. Dolor. 2023; 30(1): 30-35 / DOI: 10.20986/resed.2023.4023/2022

Review of the remission and management of a cancer related pain population to a pain unit. What can we improve?

Rev. Soc. Esp. Dolor. 2023; 30(1): 7-14 / DOI: 10.20986/resed.2023.4010/2022

Treatment of painful scars with 5 % lidocaine patch: clinical cases report

Rev. Soc. Esp. Dolor. 2022; 29(3): 187-191 / DOI: 10.20986/resed.2022.3997/2022

Long-term effectiveness of epidural steroid injections after new episodes of low back pain in older adults

Rev. Soc. Esp. Dolor. 2022; 29(3): 175-186 / DOI: 10.1002/ejp.1975

Usefulness of percutaneous basivertebral nerve thermorizotomy for the treatment of chronic low back pain. Literature review

Rev. Soc. Esp. Dolor. 2022; 29(3): 169-174 / DOI: 10.20986/resed.2022.4044/2022

Psychological intervention program to promoted active coping in patients with chronic back pain

Rev. Soc. Esp. Dolor. 2022; 29(3): 149-156 / DOI: 10.20986/resed.2022.3993/2022

Can we modify the evolution of neuropathic pain through the skin?

Rev. Soc. Esp. Dolor. 2022; 29(3): 129-131 / DOI: 10.20986/resed.2022.4052/2022

Cross-sectional study on factors related to chronic pain and its care, according to sex

Rev. Soc. Esp. Dolor. 2022; 29(2): 61-70 / DOI: 10.20986/resed.2022.3968/2022

Attitudes and current knowledge of the spanish pain treatment specialist regarding medical cannabis

Rev. Soc. Esp. Dolor. 2022; 29(13): 52-57 / DOI: 10.20986/resed.2022.4032/2022

Practical aspects of product selection and titration with medical cannabis for chronic pain management

Rev. Soc. Esp. Dolor. 2022; 29(13): 43-51 / DOI: 10.20986/resed.2022.4031/2022

Cannabinoids in neuropathic pain: lights and shadows

Rev. Soc. Esp. Dolor. 2022; 29(13): 20-26 / DOI: 10.20986/resed.2022.4027/2022

Bone pain management with opioid medication in a patient with Camurati-Engelmann disease: a case report

Rev. Soc. Esp. Dolor. 2022; 29(1): 51-55 / DOI: 10.20986/resed.2021.3930/2021

Evaluation of the analgesic efficacy of lumbar facet block as a function of the imaging technique used: ultrasound versus fluoroscopy

Rev. Soc. Esp. Dolor. 2022; 29(1): 15-20 / DOI: 10.20986/resed.2022.3969/2021

OFA in major surgery. Experience at a secondary level hospital

Rev. Soc. Esp. Dolor. 2022; 29(1): 8-14 / DOI: 10.20986/resed.2022.3991/2022

Peroneal neuropathy caused by an extraneural ganglion: literary review and treatment proposal. A non-positive case

Rev. Soc. Esp. Dolor. 2021; 28(6): 354-357 / DOI: 10.20986/resed.2022.3919/2021

New opioids with different intracellular mechanism of action; is a new therapeutic window opening up?

Rev. Soc. Esp. Dolor. 2021; 28(5): 292-297 / DOI: 10.20986/resed.2021.3891/2021

Descriptive study on the profile of patients sent to the Chronic Pain Treatment Unit of the University Hospital of Gran Canaria Dr. Negrín (UTDC-HUGCDN) as a basis for the reorganization of this

Rev. Soc. Esp. Dolor. 2021; 28(5): 254-263 / DOI: 10.20986/resed.2021.3939/2021

Capsaicin: a treatment to pick the mouth

Rev. Soc. Esp. Dolor. 2021; 28(5): 252-253 / DOI: 10.20986/resed.2021.3961/2021

Genicular nerve radiofrequency in osteoarthritis-related chronic knee pain

Rev. Soc. Esp. Dolor. 2021; 28(3): 154-168 / DOI: 10.20986/resed.2021.3900/2021

Observational and prospective study on the effectiveness and safety of the dorsal root ganglion stimulation in patients with refractory neuropathic pain

Rev. Soc. Esp. Dolor. 2021; 28(2): 148-156 / DOI: 10.20986/resed.2021.3879/2020

Prescribing habits for neuropathic pain management in Spain: results of the survey of the neuropathic pain working group of the Spanish Pain Society

Rev. Soc. Esp. Dolor. 2021; 28(3): 137-147 / DOI: 10.20986/resed.2021.3911/2021

Neuropathic pain: a constant challenge

Rev. Soc. Esp. Dolor. 2021; 28(2): 111-114 / DOI: 10.20986/resed.2021.3938/2021

Botulinum toxin for the treatment of myofascial pain syndrome

Rev. Soc. Esp. Dolor. 2021; 28(2): 100-110 / DOI: 10.20986/resed.2021.3902/2021

Evolution of low back pain in cancer patients treated with interventional pain management

Rev. Soc. Esp. Dolor. 2021; 28(2): 76-81 / DOI: 10.20986/resed.2021.3901/2021

Analgesic effectiveness of tapentadol in neuropathic pain secondary to post-laminectomy syndrome

Rev. Soc. Esp. Dolor. 2021; 28(2): 71-75 / DOI: 10.20986/resed.2021.3822/2020

Parsonage-turner after rabies vaccination due to bat bite: case report

Rev. Soc. Esp. Dolor. 2021; 28(1): 57-61 / DOI: 10.20986/resed.2021.3832/2020

Management and perception of therapeutic adherence of breakthrough cancer pain by oncologists in Spain

Rev. Soc. Esp. Dolor. 2021; 28(1): 19-26 / DOI: 10.20986/resed.2021.3824/2020

Implementation and evaluation of a multimodal analgesia protocol for total knee arthroplasty including ultrasoundguided adductor canal block and periarticular local anesthetic infiltration

Rev. Soc. Esp. Dolor. 2021; 28(1): 9-18 / DOI: 10.20986/resed.2021.3847/2020

Interventional management of osteoarthritic pain

Rev. Soc. Esp. Dolor. 2021; 28(13): 85-90 / DOI: 10.20986/resed.2021.3853/2020

Adaptation of the chronic pain unit of the Hospital Complex from Vigo to the state of alarm due to the SARS-CoV-2 pandemic

Rev. Soc. Esp. Dolor. 2020; 27(6): 392-393 / DOI: 10.20986/resed.2020.3827/2020

Transitional pain clinic

Rev. Soc. Esp. Dolor. 2020; 27(6): 369-374 / DOI: 10.20986/resed.2020.3840/2020

Therapeutic failure of the lumbar medial branch block and its relation to obesity. Retrospective cohort study

Rev. Soc. Esp. Dolor. 2020; 27(5): 298-305 / DOI: 10.20986/resed.2020.3829/2020

Identification of signs and symptoms for the diagnosis of discogenic low back pain: mapping review

Rev. Soc. Esp. Dolor. 2020; 27(5): 292-297 / DOI: 10.20986/resed.2020.3803/2020

Efficacy of lidocaine perfusions in fibromyalgia: a prospective cohort study

Rev. Soc. Esp. Dolor. 2020; 27(5): 287-291 / DOI: 10.20986/resed.2020.3796/2020

Splanchnic nerve block for the treatment of benign chronic abdominal pain. a case report and literature review

Rev. Soc. Esp. Dolor. 2020; 27(4): 273-277 / DOI: 10.20986/resed.2020.3818/2020

Clinical pathophysiology in patients with sickle cell disease: the transition from acute to chronic pain

Rev. Soc. Esp. Dolor. 2020; 27(4): 257-268 / DOI: 10.20986/resed.2020.3814/2020

Incidence of postmastectomy pain syndrome. Retrospective analysis

Rev. Soc. Esp. Dolor. 2020; 27(4): 246-251 / DOI: 10.20986/resed.2020.3797/2020

Sociodemographic and clinical characterization in patients with chronic back pain, Cienfuegos 2019

Rev. Soc. Esp. Dolor. 2020; 27(4): 239-245 / DOI: 10.20986/resed.2020.3798/2020

Metamizole as an immunomodulator in neuropathic pain

Rev. Soc. Esp. Dolor. 2020; 27(4): 230-231 / DOI: 10.20986/resed.2020.3838/2020

Analgesic effect of the capsaicin 8 % patch through the TRPV-1 receptor in a case of parkinson desease with located neuropathic pain

Rev. Soc. Esp. Dolor. 2020; 27(3): 216-22 / DOI: 10.20986/resed.2020.3786/2019

Biomechanical factors related to surgical outcomes on patients treated with lumbar arthrodesis in a high complexity center in Colombia

Rev. Soc. Esp. Dolor. 2020; 27(3): 160-167 / DOI: 10.20986/resed.2020.3759/2019

Erector spinalis plane block as a neuropathic pain management in post-burned pediatric patient

Rev. Soc. Esp. Dolor. 2020; 27(2): 127-132 / DOI: 10.20986/resed.2020.3776/2019

Efficacy of a preincisional analgesic strategy with ibuprofen, paracetamol and dexamethasone in laparoscopic cholecystectomy. Prospective observational study

Rev. Soc. Esp. Dolor. 2020; 27(2): 104-112 / DOI: 10.20986/resed.2020.3778/2019

E-consults, a new tool for pain management. Results of its implementation in an organizational structure of integrated management (EOXI)

Rev. Soc. Esp. Dolor. 2020; 27(2): 97-103 / DOI: 10.20986/resed.2020.3756/2019

Ethical problems in the management of pain. Qualitative study through open reflection interview

Rev. Soc. Esp. Dolor. 2020; 27(2): 89-96 / DOI: 10.20986/resed.2020.3729/2019

Review of the impact of acupuncture treatment on the management of nonspecific low back pain

Rev. Soc. Esp. Dolor. 2020; 27(1): 53-58 / DOI: 10.20986/resed.2020.3762/2019

Effectiveness of the association of lacosamide in trigeminal neuralgia

Rev. Soc. Esp. Dolor. 2020; 27(1): 50-52 / DOI: 10.20986/resed.2019.3738/2019

Efficacy of pregabalin, gabapentin and duloxetine in neuropathic pain verified by the p-curve analysis

Rev. Soc. Esp. Dolor. 2020; 27(1): 16-23 / DOI: 10.20986/resed.2020.3727/2019

Quasi-experimental study on effectiveness of music therapy to reduce anxiety before an interventional technique in the pain unit

Rev. Soc. Esp. Dolor. 2020; 27(1): 7-15 / DOI: 10.20986/resed.2020.3767/2019

Neurolytic procedures for pancreatic cáncer pain: a systematic review and a proposal for an algorithm treatment

Rev. Soc. Esp. Dolor. 2019; 26(6): 342-358 / DOI: 10.20986/resed.2019.3715/2018

Applicability of scales/indicators for pain monitoring in critically ill patients incapable of verbalizing: a systematic review of the literature

Rev. Soc. Esp. Dolor. 2019; 26(5): 293-303 / DOI: 10.20986/resed.2019.3726/2019

New strategies for postoperative pain control in tonsillectomy surgery. Is all that glitters gold?

Rev. Soc. Esp. Dolor. 2019; 26(5): 270-275 / DOI: 10.20986/resed.2019.3742/2019

New ACP guidelines for non-radicular low back pain

Rev. Soc. Esp. Dolor. 2019; 26(4): 254-254 / DOI: 10.20986/resed.2017.3590/2017

Open-label, prospective, safety, tolerability and sensory function study after of capsaicin 8 % patch repeat treatment in non-diabetic peripheral neuropathic pain: stride study

Rev. Soc. Esp. Dolor. 2019; 26(4): 251-252 / DOI: 10.20986/resed.2017.3564/2017

Role of depressive symptomatology, catastrophism and expectation in the efficacy of interventional treatment in chronic low back pain

Rev. Soc. Esp. Dolor. 2019; 26(4): 227-232 / DOI: 10.20986/resed.2019.3704/2018

Characterization of pain in patients with breast cancer attending the Oncology Unit of the San José Hospital

Rev. Soc. Esp. Dolor. 2019; 26(4): 221-226 / DOI: 10.20986/resed.2019.3692/2018

Optimization of postoperative pain management based on a new technological tool. Pain map

Rev. Soc. Esp. Dolor. 2019; 26(3): 154-165 / DOI: 10.20986/resed.2019.3696/2018

Explanations on the article “Recommendations based on evidence for the management of neuropathic pain (review of the literature)”

Rev. Soc. Esp. Dolor. 2019; 26(2): 134-137 / DOI: 10.20986/resed.2019.3723/2019

Main pharmacodynamic differences and receptor affinities between serotonin-norepinephrine reuptake inhibitors: clinical implications in the management of neuropathic pain

Rev. Soc. Esp. Dolor. 2019; 26(2): 131-133 / DOI: 10.20986/resed.2017.3597/2017

Does pregabalin is a safe drug? Heart failure associated with pregabalin

Rev. Soc. Esp. Dolor. 2019; 26(2): 124-125 / DOI: 10.20986/resed.2017.3537/2016

New indication of capsaicin 8 % patch: painful diabetic peripheral neuropathy

Rev. Soc. Esp. Dolor. 2019; 26(1): 60-61 / DOI: 10.20986/resed.2017.3556/2016

Project adapta: adequacy of treatment in breakthrough cancer pain

Rev. Soc. Esp. Dolor. 2019; 26(1): 31-43 / DOI: 10.20986/resed.2018.3661/2018

Micro RNAs: A new way for the management of neuropathic pain?

Rev. Soc. Esp. Dolor. 2019; 26(1): 2-3 / DOI: 10.20986/resed.2019.3730/2019

Dysphonia as side-effect dose-dependent during treatment with duloxetine

Rev. Soc. Esp. Dolor. 2018; 25(6): 359-359 / DOI: 10.20986/resed.2017.3528/2016

Evidence-based recommendations for the management of neuropathic pain (review of the literature)

Rev. Soc. Esp. Dolor. 2018; 25(6): 349-358 / DOI: 10.20986/resed.2018.3673/2018

Experience in two hospitals about the observation of pain responses in hospitalized preterm infants

Rev. Soc. Esp. Dolor. 2018; 25(5): 271-277 / DOI: 10.20986/resed.2018.3633/2017

Platelet-rich plasma in treating peripheral neuropathic pain. Preliminary report

Rev. Soc. Esp. Dolor. 2018; 25(5): 263-270 / DOI: 10.20986/resed.2017.3625/2017

Pharmacological management of acute postoperative pain in Spain. Data from the national survey by the Spanish Pain Society (SED)

Rev Soc Esp Dolor 2018; 25(2): 70-85 / DOI: 10.20986/resed.2017.3593/2017

Pain management in cancer patients receiving radiotherapy: GORVAMUR study, a prospective, observational, epidemiological study

Rev Soc Esp Dolor 2017; 24(5): 241-255 / DOI: 10.20986/resed.2017.3570/2017

Prevalence of breakthrough pain associated with chronic low back pain in Andalusia (COLUMBUS study)

Rev Soc Esp Dolor 2017; 24(3):116-124 / DOI: 10.20986/resed.2017.3548/2016

Factors associated with pain intensity in Mexican patients hospitalized in postoperative period

Rev Soc Esp Dolor 2017; 24(1): 4-10 / DOI: 10.20986/resed.2016.3442/2016

Instrucciones para citar

López M, López J, López J, García M. Use of 8 % capsaicin patches for the treatment of lumbar neuropathic pain. Rev Soc Esp Dolor 2022; 29(1): 28-33 / DOI: 1020986/resed20223995/2022


Descargar a un gestores de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica

Este artículo ha sido visitado 12995 veces.
Este artículo ha sido descargado 8 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 30/05/2022

Aceptado: 07/07/2022

Prepublicado: 19/07/2022

Publicado: 05/08/2022

Tiempo de revisión del artículo: 0 días

Tiempo de prepublicación: 50 días

Tiempo de edición del artículo: 67 días


Compartir

Este artículo aun no tiene valoraciones.
Reader rating:
Rate this article:
Send by e-mail
© 2024 Revista de la Sociedad Española del Dolor
ISSN: 1134-8046   e-ISSN: 2254-6189

       Indexada en:
Política de Privacidad